362 related articles for article (PubMed ID: 21996197)
21. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation.
Albano L; Buchler M; Cantarovich D; Cassuto E; Cointault O; Mazouz H; Vetromile F; Lecuyer A; Tindel M; Kamar N
Ann Transplant; 2016 Apr; 21():250-61. PubMed ID: 27122116
[TBL] [Abstract][Full Text] [Related]
22. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
25. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.
Legendre C; Cohen D; Zeier M; Rostaing L; Budde K
Transplant Proc; 2007 Jun; 39(5):1386-91. PubMed ID: 17580145
[TBL] [Abstract][Full Text] [Related]
27. Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients.
Chang HR; Lin CC; Lian JD
Transplant Proc; 2005 Jun; 37(5):2066-8. PubMed ID: 15964340
[TBL] [Abstract][Full Text] [Related]
28. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
[TBL] [Abstract][Full Text] [Related]
29. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
30. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
[TBL] [Abstract][Full Text] [Related]
31. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplantation.
Lee SH; Park JB; Oh CK; Kim MS; Kim SJ; Ha J
Yonsei Med J; 2017 Jan; 58(1):217-225. PubMed ID: 27873516
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.
Arns W; Sommerer C; Glander P; Ariatabar T; Porstner M; May C; Paulus EM; Shipkova M; Fischer W; Liefeldt L; Hackenberg R; Schemmer P; Domhan S; Zeier M; Budde K
Clin Nephrol; 2013 Jun; 79(6):421-31. PubMed ID: 23611518
[TBL] [Abstract][Full Text] [Related]
34. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study.
Vogt B; Antoniadis A; Klinger M; Vitko S
Transplant Proc; 2006 Jun; 38(5):1301-6. PubMed ID: 16797288
[TBL] [Abstract][Full Text] [Related]
36. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
[TBL] [Abstract][Full Text] [Related]
37. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
[TBL] [Abstract][Full Text] [Related]
38. Use of mycophenolate sodium in stable renal transplant recipients in Spain: preliminary results of the MIDATA study.
Sánchez-Fructuoso A; Ruiz JC; Rengel M; Andrés A; Morales JM; Beneyto I; Guirado LI; Cantarell C;
Transplant Proc; 2009; 41(6):2309-12. PubMed ID: 19715904
[TBL] [Abstract][Full Text] [Related]
39. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study.
Zhang H; Liu L; Li J; Fu Q; Wan J; Deng R; Wang H; Liao J; Deng W; Deng S; Chen L; Wang C
Int J Clin Pract; 2016 Jun; 70 Suppl 185():22-30. PubMed ID: 27198001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
